Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management.
聖地亞哥，2024年5月1日（環球新聞專線）——專注於開發新型腫瘤療法的臨床階段生物製藥公司Oncternal Therapeutics, Inc.（納斯達克股票代碼：ONCT）今天宣佈批准向即將加入Oncternal擔任臨床數據管理高級董事的新員工安妮·漢森發放激勵獎勵。
The award will be made on May 1, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 5,000 shares of Oncternal common stock. The option will have a 10-year term and an exercise price equal to the closing price of Oncternal's common stock on the date of grant. The option will vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the employee's start date, and the rest vesting in equal monthly installments over three years thereafter. The award was approved by Oncternal's compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and will be granted as an inducement material to the employee entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).
該獎勵將於2024年5月1日根據Oncternal的2021年就業激勵獎勵計劃發放，該計劃規定向Oncternal的新員工發放股權獎勵，以此作爲加入公司的誘因。該獎勵將包括購買5,000股Oncternal普通股的期權。該期權的期限爲10年，行使價等於授予之日Oncternal普通股的收盤價。該期權將在四年內歸屬，25％的股份將在員工入職一週年之際歸屬，其餘股份將在其後的三年內按月等額分期歸屬。根據納斯達克規則5635（c）（4）的要求，該獎勵已獲得Oncternal薪酬委員會的批准，該薪酬委員會完全由獨立董事組成，並將作爲激勵材料發放給根據納斯達克規則5635（c）（4）在Oncternal工作的員工。
About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. ONCT-534 is an investigational dual-action androgen receptor inhibitor (DAARI) with demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR aberration. It is a potential treatment for patients with mCRPC with unmet medical need because of resistance to androgen receptor pathway inhibitors, including those with AR amplification, mutations in the AR ligand binding domain (LBD), or splice variants with loss of the AR LBD. Study ONCT-534-101 (NCT05917470) has completed enrollment in three dose cohorts and continues to enroll and dose patients for treatment with mCRPC. ONCT-808 is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T therapy to be produced, compared with currently approved CAR T products. Oncternal has dosed patients under Study ONCT-808-101 (NCT05588440) with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment. Zilovertamab is an investigational monoclonal antibody designed to inhibit the function of ROR1. Zilovertamab has been evaluated in a Phase 1/2 Study CIRM-0001 (NCT03088878) in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL), which resulted in 100% progression free survival (PFS) at 42 months in CLL patients expressing a p53 mutation/del(17p), a population underserved by current treatment options. Zilovertamab is also being evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (NCT05156905). More information on our company and programs is available at
關於 Internal Therapeutics
Oncternal Therapeutics是一家處於臨床階段的生物製藥公司，專注於開發新的腫瘤療法，以治療尚未滿足的關鍵醫療需求的癌症患者。Oncternal致力於針對與癌症產生或進展相關的有前景但尚未開發的生物學途徑進行藥物開發，重點是血液系統惡性腫瘤和前列腺癌。ONCT-534 是一種正在研究的雙效雄激素受體抑制劑 (DAARI)，在前列腺癌模型中表現出對未突變的雄激素受體 (AR) 和多種形式的 AR 像差的臨床前活性。對於因對雄激素受體途徑抑制劑產生耐藥性而醫療需求未得到滿足的mcRPC患者，包括具有AR擴增作用、AR配體結合域（LBD）突變或缺失AR LBD的剪接變異的患者，它是一種潛在的治療方法。ONCT-534-101（NCT05917470）研究已經完成了三個劑量組的入組，並繼續招募和給患者服用mcRPC治療。ONCT-808 是一種正在研究的自體嵌合抗原受體 T (CAR T) 細胞療法，使用來自齊洛維他單抗的結合結構域靶向受體酪氨酸激酶樣孤兒受體 1 (ROR1)。ONCT-808 已在針對多種血液學惡性腫瘤和實體瘤的臨床前模型中顯示出活性，並已被證明對錶達 ROR1 的癌細胞具有特異性。與目前批准的CAR T產品相比，Oncternal開發了一種穩健且可重複的製造工藝，該工藝有可能減少患者等待個人CAR-T療法生產所需的時間。Oncternal 曾在 ONCT-808-101 研究（NCT05588440）下給復發或難治性侵襲性 B 細胞淋巴瘤的患者服藥，包括先前 CD19 CAR T 治療失敗的患者。Zilovertamab是一種研究中的單克隆抗體，旨在抑制ROR1的功能。Zilovertamab已在一項1/2期研究 CIRM-0001（NCT03088878）與依魯替尼聯合治療套細胞淋巴瘤（MCL）、慢性淋巴細胞白血病（CLL）和邊緣區淋巴瘤（MZL）患者進行了評估，該研究表明 p53 突變/突變（17p）的 CLL 患者在 42 個月時無進展存活（PFS），該患者群體 p53 突變/突變（17p）由當前的治療方案提供。研究人員發起的一項針對齊洛維他單抗聯合多西他賽治療轉移性去勢抵抗性前列腺癌（NCT05156905）患者的1b期研究也在評估Zilovertamab。有關我們公司和計劃的更多信息，請訪問
Contact Information:
聯繫信息：
Investors
Richard Vincent
Chief Financial Officer
858-434-1113
rvincent@oncternal.com
投資者
理查德·文森
首席財務官
858-434-1113
rvincent@oncternal.com
Media
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
媒體
科裏·戴維斯博士
生命科學顧問
212-915-2577
cdavis@lifesciadvisors.com
譯文內容由第三人軟體翻譯。